With Risk-to-Remedies Launched, Diginex Awaits a Make-or-Break Merger Update by June 30
20.06.2026 - 16:38:20 | boerse-global.de
A string of new supply-chain transparency laws is creating a fast-growing market for due-diligence software — and Diginex is betting its entire near-term future on capturing it. In June the company rolled out “Risk-to-Remedy,” an end-to-end platform that combines LUMEN's risk-assessment tools with APPRISE's worker-engagement features and the grievance expertise of The Remedy Project. The timing looks auspicious: the global market for human-rights and supply-chain due diligence is forecast to expand from $3.8 billion in 2025 to $9.6 billion by 2034, fueled by statutes such as the EU Corporate Sustainability Due Diligence Directive, Germany’s Lieferkettensorgfaltspflichtengesetz, and the UK and Australian Modern Slavery Acts.
Yet for all that regulatory tailwind, Diginex remains a micro-cap with a market capitalisation of roughly $28 million, negative net income, and a share price that closed at $0.90 on June 17 — below the $1.00 threshold that keeps it listed on the Nasdaq. The disconnect stems largely from one unresolved transaction: the $1.5 billion all-stock acquisition of Resulticks Global Companies, first announced on April 16 at a price of $1.32 per Diginex share. The deal, which would inject roughly $150 million in annual revenue and $46 million to $50 million in EBITDA, is seen as the catalyst that could turn Diginex from a sustainability-data provider into an AI-driven customer-engagement player. But the closing deadline has already been pushed twice since the original May 29 target — first to June 12, then to the current drop-dead date of June 30.
The repeated delays have taken a toll. Diginex’s stock fell 4.33% on the latest extension announcement, adding to a 19.64% slide over the prior 30 days. The relative strength index sits at 31.5, technically in oversold territory, and annualised volatility clocks in at 125.69%. The pattern is unmistakable: even positively framed deal updates have consistently produced negative price moves.
Should investors sell immediately? Or is it worth buying Diginex?
Running on a parallel track is a separate Nasdaq-compliance deadline. In March 2026 the exchange warned Diginex after its shares had traded below $1.00 for 30 consecutive sessions. The company executed an 8-for-1 reverse stock split in late April, reducing the outstanding share count to about 29.1 million, but the stock has since slipped back under the critical level. The cure period runs until September 21, 2026, with a possible 180-day grace period if all other listing requirements remain satisfied. Failure could lead to delisting.
Both Diginex and Resulticks have pledged to issue an update by June 30. Three outcomes are possible: a completed transaction, another extension, or a full termination. If the merger goes through, Diginex will have the operational heft to capitalise on the regulatory wave. If it collapses, the company loses its most powerful growth catalyst — and will face the Nasdaq question with far less fire power. The next week will determine whether the strategic story finally gets the financial foundation it needs.
Ad
Diginex Stock: New Analysis - 20 June
Fresh Diginex information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
